特罗凯联合化疗对食管癌术后辅助治疗的临床观察  

CLINICAL OBSERVATION OF TARCEVA IN COMBINATION WITH CHEMOTHERAPY IN THE ADJUVANT POSTOPERATIVE TREATMENT

作　　者：陈永东[1] 李晓宁[1] 邵中夫[1] 

机构地区：[1]广州医科大学附属肿瘤医院,广东广州510095

出　　处：《现代医院》2014年第12期44-46,共3页Modern Hospitals

基　　金：吴阶平医学基金资助(编号:320.6700.1173)

摘　　要：目的研究特罗凯联合化疗对食管癌术后辅助治疗的临床疗效。方法将我院2010年1月~2012年1月期间收治的120例食管癌患者随机分为2组,即观察组60例,对照组60例。对照组患者行单纯化疗治疗,观察组患者行特罗凯联合化疗治疗。治疗后,分别对2组患者的临床治疗效果进行评价;分别观察并统计2组患者不良反应的发生率;同时对患者进行随访,观察并统计2组患者治疗后的无进展生存时间（PFS）和总生存期（OS）。结果观察组患者临床治疗的总有效率为75%,对照组为55%,2组比较,差异具有统计学意义（p〈0.05）。观察组患者恶心呕吐、肝功能异常、感觉神经异常、白细胞减少、皮疹及腹胀腹泻不良反应的发生率依次为21.67%、15%、50%、30%、23.33%、25%;对照组依次为：20%、16.67%、48.33%、33.33%、18.33%、21.67%,2组比较,差异无统计学意义（p〉0.05）。观察组患者的平均PFS和OS依次为（5.3±1.1）月、（10.2±2.3）月;对照组依次为（3.6±1.3）月、（8.4±2.2）月,2组比较,差异具有统计学意义（p〈0.05）。结论特罗凯联合化疗对食管癌术后辅助治疗的临床疗效要优于单纯化疗,且不良反应较轻,能有效延长患者的无进展生存时间和总生存期,值得临床推广与应用。Objective To study the clinical efficacy of tarceva in combination with chemotherapy for esoph- ageal cancer in postoperative adjuvant treatment. Methods Our hospital from January 2010 to January 2010 admit- ted during the period of 120 cases of esophageal cancer patients were randomly divided into 2 groups ： the observation group （60 cases） and control group （60 cases）. Patients in control group took chemotherapy treatment, and observa- tion group patients received tarceva combination chemotherapy treatment. After treatment, the clinical therapeutic effect of two groups patients were evaluated, respectively. The incidence of adverse reactions for 2 groups of patients was observed. At the same time, the observation and statistics of two groups after treatment in patients with progres- sion- free survival （PFS） and overall survival （OS） were followed. Results The observation group of patients＇ clinical total effective rate was 75% and control group was 55%, compared two groups. The difference have statistical significance （p 〈 O. 05）. The incidences of observation group of patients with nausea and vomiting, abnormal liver function and abnormal sensory nerve, 1eukopenia, skin rashes and abdominal distension diarrhoea were 21.67%, 15%, 50%, 30%, 23.33% and 25% ; The incidences of control group were 20%, 16. 67%, 48. 33%, 33.33%, 18. 33% and 21.67%. There was no statistically significant difference （p 〉 0. 05）. The observation group of patients had an average of PFS and OS （5.3 -＋ 1.1 ）, （ 10. 2 ＋ 2. 3 ） months ; The control group patients were （3.6 ＋ 1.3 ） months and （8.4 -＋ 2.2） months. The difference has statistical significance （p 〈 0.05）. Conclusion The postoper- ative adjuvant clinical curative effect of Tarceva in combination with chemotherapy for esophageal cancer is better than simple chemotherapy curative effect, and the adverse reaction is lighter, which can effectively prolong patient＇ s overall survival and progression - free survival time,

关 键 词：食管癌 特罗凯 化疗 联合 

分 类 号：R737.33[医药卫生—肿瘤]